Clinical Trial

Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.

Study acronym: CABOPrEP
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 23, 2024 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate if offering long-acting injectable cabotegravir (CAB-LA) as an additional HIV prevention choice among oral PrEP-experienced men who have sex with men (MSM) in France can significantly increase the sustained PrEP use over time and the PrEP coverage of at-risk sexual risk behaviors.
Trial Details
NCT Number NCT06273943
Lead Sponsor ANRS, Emerging Infectious Diseases
Conditions Prevention
Enrollment 322 participants
Start Date 2024-04-01
Primary Completion 2025-10-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2024-02-23